Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement ...
By Siddhi Mahatole Sept 17 (Reuters) - Orbis Medicines said on Thursday it had signed a drug discovery and licensing ...
Novo Nordisk signs a deal worth up to $1.4bn with Orbis Medicines to develop oral drugs for cardiometabolic diseases.
Novo Nordisk (OVO) teams up with Orbis Medicine to develop oral cardiometabolic treatments—in a deal worth up to $1.4B. Read ...
Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...
Orbis Medicines announced a strategic collaboration and license agreement with Novo to discover and develop next-generation ...
Novo Nordisk A/S agreed to work with Orbis Medicines ApS on next-generation pills for heart and metabolic diseases in a ...
GlobalData on MSN
Novo targets oral macrocycles with $1.4bn Orbis partnership
The deal reflects a growing interest from big pharma in the compounds that bridge the gap between small molecules and biologics.
Novo Nordisk (NVO) stock is in focus after signing a $1.4B deal with Orbis Medicines to develop oral drugs for ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Orbis Medicines, a leader in oral macrocycle drug ...
Peptide drugs, such as the metabolic medicines Mounjaro and Zepbound from Eli Lilly, must be administered as injections. But the biotech industry has been pursuing ways to make peptides into pills, ...
Novo Nordisk stock ended September 18, 2026 at USD 43.23, and the intraday range on MarketBeat stretched from USD 42.78 to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results